haldol decanoate 50mg/ml solution for injection
janssen-cilag ltd - haloperidol decanoate - solution for injection - 50 milligram(s)/millilitre - butyrophenone derivatives; haloperidol
haldol decanoate 100mg/ml solution for injection
janssen sciences ireland uc - haloperidol - solution for injection - 100 milligram(s)/millilitre - butyrophenone derivatives; haloperidol
haloperidol decanoate injection
gland pharma limited - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: • severe toxic central nervous system depression or comatose states from any cause. • hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). • parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ). • dementia with lewy bodies (see warnings, neurological adverse
haloperidol decanoate injection, solution
sagent pharmaceuticals - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in
haloperidol thame 1mg/ml oral solution
syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - haloperidol - oral solution - haloperidol 1 mg/ml - psycholeptics
haloperidol injection bp 5 mgml
duopharma (singapore) pte ltd - haloperidol - injection - 5 mg/ml - haloperidol 5 mg/ml
haloperidol injection
tya pharmaceuticals - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol is indicated for use in the treatment of schizophrenia. haloperidol is indicated for the control of tics and vocal utterances of tourette's disorder. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.
haloperidol 5mg/1ml solution for injection ampoules
a a h pharmaceuticals ltd - haloperidol - solution for injection - 5mg/1ml
haloperidol 5mg/1ml solution for injection ampoules
alliance healthcare (distribution) ltd - haloperidol - solution for injection - 5mg/1ml
haloperidol 5mg/1ml solution for injection ampoules
special order - haloperidol - solution for injection - 5mg/1ml